Get the Stockscreener App
3.65
0.27%
0.010
After Hours:
3.80
0.15
+4.11%
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
What is HC Wainwright’s Estimate for AMLX FY2025 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - Markets Insider
What is HC Wainwright’s Estimate for AMLX Q1 Earnings? - Defense World
Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position - TipRanks
HC Wainwright Reiterates “Buy” Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells $14,549 in stock By Investing.com - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
Y Intercept Hong Kong Ltd Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
March 2025's Top Penny Stocks To Watch - Yahoo Finance
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 30.5% in February - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals chief legal officer sells $5,022 in stock By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells $14,549 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $5,022 in stock - Investing.com
Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market - TipRanks
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Co-CEOs Cash In on Stock Sales! - TipRanks
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation - TipRanks
Amylyx Pharmaceuticals Reports 2024 Financial Results - TipRanks
Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress - TipRanks
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Amylyx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Amylyx Pharmaceuticals shares rise nealy 5% on Q4 earnings beat By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals shares rise nealy 5% on Q4 earnings beat - Investing.com
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - Joplin Globe
Earnings Scheduled For March 4, 2025 - Benzinga
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders - ACCESS Newswire
AMLX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Blue Trust Inc. Purchases 4,883 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Top Executive Sells Thousands in Amylyx Pharmaceuticals Stock! - TipRanks
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery - Seeking Alpha
Q4 Earnings Preview: Can Amylyx Pharmaceuticals Deliver Strong 2024 Results? - StockTitan
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - The Bakersfield Californian
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
IMMINENT AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Amylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on Thursday - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA clears Amylyx to resume ALS drug trial in North America - MSN
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: A Comprehensive Overview and Future Outlook - EIN News
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):